CGT Catapult’s third annual clinical adoption workshop offers recommendations for advancing institutional readiness across the NHS to accelerate the routine adoption of cell and gene therapies

Representatives from the NHS, industry and government organisations have been brought together by the CGT Catapult to define feasible strategies and solutions which can address the specific needs in setting up and delivering advanced therapy clinical trials. The initiative was organised by the CGT Catapult in partnership with the Association of the British Pharmaceutical Industry (ABPI) and BioIndustry Association (BIA) to ensure the UK remains a global leader in delivering ATMP clinical trials and supports their future adoption.  The output of this workshop has been published in a report today.

To ensure the UK remains a competitive and economically viable place to set up and deliver ATMP clinical trials, creates an environment which enables global decision makers to prioritise the UK and successfully leverages available clinical data for health technology assessment (HTA), all present stakeholders agreed that the recommendations to take forward should focus on: 

• Regulatory and clinical stakeholders increasing the resources available to support clinicians and industry to navigate the set-up of trials, including support for rapid trial set-up.
   
• All ATMP stakeholders continuing to build and maintain the positive collaboration work between all parties to enhance acceptance and routine use of innovative clinical trials and ATMP adoption mechanisms.
   
• Manufacturers, regulatory bodies, the National Institute for Health and Care and Excellence (NICE) and NHS working together to implement strategies which can mitigate against trial data challenges and optimise the HTA process.

These annual workshops continue to serve as an invaluable opportunity for stakeholders from across the cell and gene therapy landscape to assess the latest industry challenges and define an effective response. This year’s initiatives set the scene for impactful activities to be taken forward in collaboration to advance the routine adoption of cell and gene therapies across the NHS.

A summary of outputs can be found here.